RESUMO
High genetic and phenotypic variability between Leishmania species and strains within species make the development of broad-spectrum antileishmanial drugs challenging. Thus, screening panels consisting of several diverse Leishmania species can be useful in enabling compound prioritization based on their spectrum of activity. In this study, a robust and reproducible high content assay was developed, and 1280 small molecules were simultaneously screened against clinically relevant cutaneous and visceral species: L. amazonensis, L. braziliensis, and L. donovani. The assay is based on THP-1 macrophages infected with stationary phase promastigotes and posterior evaluation of both compound antileishmanial activity and host cell toxicity. The profile of compound activity was species-specific, and out of 51 active compounds, only 14 presented broad-spectrum activity against the three species, with activities ranging from 52% to 100%. Notably, the compounds CB1954, Clomipramine, Maprotiline, Protriptyline, and ML-9 presented pan-leishmanial activity, with efficacy greater than 70%. The results highlight the reduced number of compound classes with pan-leishmanial activity that might be available from diversity libraries, emphasizing the need to screen active compounds against a panel of species and strains. The assay reported here can be adapted to virtually any Leishmania species without the need for genetic modification of parasites, providing the basis for the discovery of broad spectrum anti-leishmanial agents.
Assuntos
Leishmaniose/tratamento farmacológico , Animais , Antiprotozoários/uso terapêutico , Avaliação Pré-Clínica de Medicamentos , Humanos , Leishmania/efeitos dos fármacos , Leishmania/patogenicidade , Leishmaniose Visceral/tratamento farmacológico , Maprotilina/química , Camundongos , Protriptilina/química , Especificidade da Espécie , Células THP-1RESUMO
Objective: Despite the recognized anti-inflammatory potential of heterocyclic antidepressants, the mechanisms concerning their modulating effects are not completely known. Thus, we evaluated the anti-inflammatory effect of amitriptyline, clomipramine, and maprotiline and the possible modulating properties of these drugs on neutrophil migration and mast cell degranulation. Methods: The hind paw edema and air-pouch models of inflammation were used. Male Wistar rats were treated with saline, amitriptyline, clomipramine or maprotiline (10, 30, or 90 mg/kg, per os [p.o.]) 1 h before the injection of carrageenan (300 μg/0.1 mL/paw) or dextran (500 μg/0.1 mL/paw). Then, edema formation was measured hourly. Neutrophil migration to carrageenan (500 μg/pouch) and N-formyl-methionyl-leucyl-phenylalanine (fMLP) (10-6 M/mL/pouch) was also investigated in 6-day-old air-pouch cavities. Compound 48/80-induced mast cell degranulation was assessed in the mesenteric tissues of antidepressant-treated rats. Results: All tested antidepressants prevented both carrageenan- and dextran-induced edema. The anti-inflammatory effect of these drugs partially depends on the modulation of neutrophil migration, since they significantly counteracted the chemotactic response of both carrageenan and fMLP (p < 0.01). Furthermore, amitriptyline, clomipramine and maprotiline inhibited compound 48/80-induced mast cell degranulation (p < 0.001). Conclusions: These results suggest an important anti-inflammatory role of heterocyclic antidepressants, which is dependent on the modulation of neutrophil migration and mast cell stabilization. .
Assuntos
Animais , Masculino , Ratos , Amitriptilina/farmacologia , Anti-Inflamatórios/farmacologia , Degranulação Celular/efeitos dos fármacos , Clomipramina/farmacologia , Maprotilina/farmacologia , Mastócitos/efeitos dos fármacos , Infiltração de Neutrófilos/efeitos dos fármacos , Carragenina/efeitos adversos , Movimento Celular/efeitos dos fármacos , Modelos Animais de Doenças , Edema/induzido quimicamente , Mastócitos/fisiologia , Ratos WistarRESUMO
OBJECTIVE: Despite the recognized anti-inflammatory potential of heterocyclic antidepressants, the mechanisms concerning their modulating effects are not completely known. Thus, we evaluated the anti-inflammatory effect of amitriptyline, clomipramine, and maprotiline and the possible modulating properties of these drugs on neutrophil migration and mast cell degranulation. METHODS: The hind paw edema and air-pouch models of inflammation were used. Male Wistar rats were treated with saline, amitriptyline, clomipramine or maprotiline (10, 30, or 90 mg/kg, per os [p.o.]) 1 h before the injection of carrageenan (300 µg/0.1 mL/paw) or dextran (500 µg/0.1 mL/paw). Then, edema formation was measured hourly. Neutrophil migration to carrageenan (500 µg/pouch) and N-formyl-methionyl-leucyl-phenylalanine (fMLP) (10-6 M/mL/pouch) was also investigated in 6-day-old air-pouch cavities. Compound 48/80-induced mast cell degranulation was assessed in the mesenteric tissues of antidepressant-treated rats. RESULTS: All tested antidepressants prevented both carrageenan- and dextran-induced edema. The anti-inflammatory effect of these drugs partially depends on the modulation of neutrophil migration, since they significantly counteracted the chemotactic response of both carrageenan and fMLP (p < 0.01). Furthermore, amitriptyline, clomipramine and maprotiline inhibited compound 48/80-induced mast cell degranulation (p < 0.001). CONCLUSIONS: These results suggest an important anti-inflammatory role of heterocyclic antidepressants, which is dependent on the modulation of neutrophil migration and mast cell stabilization.
Assuntos
Amitriptilina/farmacologia , Anti-Inflamatórios/farmacologia , Degranulação Celular/efeitos dos fármacos , Clomipramina/farmacologia , Maprotilina/farmacologia , Mastócitos/efeitos dos fármacos , Infiltração de Neutrófilos/efeitos dos fármacos , Animais , Carragenina/efeitos adversos , Movimento Celular/efeitos dos fármacos , Modelos Animais de Doenças , Edema/induzido quimicamente , Masculino , Mastócitos/fisiologia , Ratos , Ratos WistarRESUMO
Alterations in cardiac function were observed in antidepressants treated patients and published in several clinical reports. These detected changes could be either a consequence of the treatment or of depression itself, which has already been proved to be a risk factor in heart diseases. In order to determine a possible influence of chronic treatment with norepinephrinergic reuptake inhibitor, maprotiline, on the heart, we investigated gene expression of cardiac β-adrenoceptors both in controls and in animals with signs of depression. The rats were divided into two groups, unstressed controls and those exposed to chronic unpredictable mild stress (CUMS). The groups were further divided into two subgroups, one receiving daily intraperitoneal injections of vehicle (sterile water) and another one maprotiline (10 mg/kg) for four weeks. Tissue samples were collected after the last application. Gene expression of cardiac β1- and β2-adrenoceptor was determined using Real-time RT-PCR analysis. Our results show that in control animals expression of both adrenoreceptors was decreased in the right atria after 4 weeks of maprotiline application. Contrary, the same treatment led to a significant increase in expression of cardiac β1-adrenoceptor in the stressed rats, with no change in the characteristics of β2-adrenoceptor. Our findings might reflect the that molecular mechanisms are underlying factors involved in the development of cardiovascular diseases linked with antidepressant treatment.
Vários relatórios clínicos observaram alterações de funcionamento cardíaco de pacientes depressivos que foram tratados com os antidepressivos. As alterações detectadas podem ser consequência do tratamento ou, por outro lado, da depressão que, como se tem provado, é um fator de risco no caso de doenças cardíacas. De modo a determinar a possível influência de tratamento crônico com o inibidor da recaptação de norepinefrina, maprotilina, no coração, foi investigada a expressão do gene aos receptores β-adrenérgicos cardíacos dos animais em grupos de controle e em grupos com sinais de depressão. Os ratos foram divididos em grupos de controle não estressados e os grupos de ratos submetidos ao estresse crônico moderado imprevisível (CUMS). Os grupos foram, ainda, divididos em dois subgrupos, que, durante quatro semanas, diariamente receberam injeções intraperitoneais de placebo (água estéril) ou de maprotilina (10 mg/kg). As amostras de tecido foram coletadas após a última aplicação. A expressão do gene aos receptores adrenérgicos β1 e β2 foi determinada utilizando a análise PCR quantitativa em tempo real (RT-PCR). Os nossos resultados demonstram a diminuição de expressão dos ambos os receptores adrenérgicos no átrio direito dos animais do grupo de controle depois de quatro semanas de aplicação de maprotilina. Em contraste, o mesmo tratamento conduziu ao aumento significativo na expressão do receptor β1-adrenérgico no coração dos ratos estressados, sem qualquer alteração nas características do receptor β2-adrenérgico. Estes resultados podem refletir os mecanismos moleculares envolvidos no desenvolvimento de doenças cardiovasculares associadas ao tratamento com os antidepressivos.
Assuntos
Ratos , Receptores Adrenérgicos/análise , Maprotilina , Antidepressivos/classificação , Doenças Cardiovasculares/classificação , Expressão Gênica , DepressãoRESUMO
OBJECTIVES: The purpose of this work was to determine whether the intraperitoneal administration of glibenclamide as a K ATP channel blocker could have an effect on the antinociceptive effects of antidepressants with different mechanisms of action. METHODS: Three antidepressant drugs, amitriptyline as a dual-action, nonselective inhibitor of noradrenaline and a serotonin reuptake inhibitor, fluvoxamine as a selective serotonin reuptake inhibitor and maprotiline as a selective noradrenaline reuptake inhibitor, were selected, and the effect of glibenclamide on their antinociceptive activities was assessed in male Swiss mice (25-30 g) using a formalin test. DISCUSSION: None of the drugs affected acute nociceptive responses during the first phase. Amitriptyline (5, 10 mg/ kg), maprotiline (10, 20 mg/kg) and fluvoxamine (20 and 30 mg/kg) effectively inhibited pain induction caused by the second phase of the formalin test. Glibenclamide (5 mg/kg) alone did not alter licking behaviors based on a comparison with the control group. However, the pretreatment of animals with glibenclamide (10 and 15 mg/kg) partially reversed the antinociceptive effects of fluvoxamine but not those of maprotiline. In addition, the highest dose of glibenclamide (15 mg/kg) partially prevented the analgesic effect of amitriptyline. CONCLUSION: Therefore, it seems that adenosine triphosphate-dependent potassium channels have a major role in the analgesic activity of amitriptyline and fluvoxamine.
Assuntos
Analgésicos/uso terapêutico , Antidepressivos/uso terapêutico , Glibureto/farmacologia , Medição da Dor/efeitos dos fármacos , Bloqueadores dos Canais de Potássio/farmacologia , Canais de Potássio/efeitos dos fármacos , Amitriptilina/uso terapêutico , Análise de Variância , Animais , Interações Medicamentosas , Fluvoxamina/uso terapêutico , Masculino , Maprotilina/uso terapêutico , Camundongos , Modelos Animais , Dor/induzido quimicamente , Dor/tratamento farmacológico , Distribuição AleatóriaRESUMO
OBJECTIVES: The purpose of this work was to determine whether the intraperitoneal administration of glibenclamide as a K ATP channel blocker could have an effect on the antinociceptive effects of antidepressants with different mechanisms of action. METHODS: Three antidepressant drugs, amitriptyline as a dual-action, nonselective inhibitor of noradrenaline and a serotonin reuptake inhibitor, fluvoxamine as a selective serotonin reuptake inhibitor and maprotiline as a selective noradrenaline reuptake inhibitor, were selected, and the effect of glibenclamide on their antinociceptive activities was assessed in male Swiss mice (25-30 g) using a formalin test. DISCUSSION: None of the drugs affected acute nociceptive responses during the first phase. Amitriptyline (5, 10 mg/ kg), maprotiline (10, 20 mg/kg) and fluvoxamine (20 and 30 mg/kg) effectively inhibited pain induction caused by the second phase of the formalin test. Glibenclamide (5 mg/kg) alone did not alter licking behaviors based on a comparison with the control group. However, the pretreatment of animals with glibenclamide (10 and 15 mg/kg) partially reversed the antinociceptive effects of fluvoxamine but not those of maprotiline. In addition, the highest dose of glibenclamide (15 mg/kg) partially prevented the analgesic effect of amitriptyline. CONCLUSION: Therefore, it seems that adenosine triphosphate-dependent potassium channels have a major role in the analgesic activity of amitriptyline and fluvoxamine.
Assuntos
Animais , Masculino , Camundongos , Analgésicos/uso terapêutico , Antidepressivos/uso terapêutico , Glibureto/farmacologia , Medição da Dor/efeitos dos fármacos , Bloqueadores dos Canais de Potássio/farmacologia , Canais de Potássio/efeitos dos fármacos , Análise de Variância , Amitriptilina/uso terapêutico , Interações Medicamentosas , Fluvoxamina/uso terapêutico , Modelos Animais , Maprotilina/uso terapêutico , Dor/induzido quimicamente , Dor/tratamento farmacológico , Distribuição AleatóriaRESUMO
BACKGROUND: Antidepressant drugs act as potent inhibitors of norepinephrine and/or serotonin reuptake and are widely used with opioids for the treatment of chronic pain. The mechanism of this increased analgesic action is unclear. We compared the antinociceptive effects of the intrathecal administration of morphine with that of a nonselective (amitriptyline) or selective (maprotiline or citalopram) antidepressant drug using the thermal withdrawal test in rats. We also investigated the possible mechanisms involved in the interactions of these drugs. METHODS: Male Wistar rats were anesthetized with sevoflurane and administered morphine and antidepressant drugs, or saline, through intrathecal injection. The antinociceptive effect was evaluated using the thermal withdrawal test before and after drug administration. The time for the withdrawal reaction was expressed as percentage of maximum possible effect (MPE). Animals were also pretreated with yohimbine (a nonselective alpha2-adrenergic antagonist) and naloxone (a nonselective opioid antagonist) for mechanism of action studies. Pharmacologic interaction was evaluated using isobolographic analysis of simultaneous administration of fixed proportions of maprotiline and morphine. RESULTS: Single intrathecal administration of morphine (2 microg), amitriptiline (125 microg), citalopram (144 microg), and maprotiline (1.25 microg) produced 51.6% +/- 8.9%, 10.3% +/- 3.2%, 33.8% +/- 5.2%, and 48.5% +/- 9.2% MPE, respectively. The antinociceptive effect of morphine was increased when combined with amitriptyline (91.3% +/- 4.6% MPE) and maprotiline (86.9% +/- 9.2% MPE) but not with citalopram (40.6% +/- 4.6% MPE). Coadministration of maprotiline increased the antinociceptive duration of morphine by 4-fold (from 120 to 480 min), which was reversed by pretreatment with the alpha-2 adrenoceptor inhibitor, yohimbine, and the mu-type opioid receptor antagonist, naloxone. Isobolographic analysis demonstrated a synergistic interaction between morphine and maprotiline. CONCLUSIONS: Selective norepinephrine reuptake inhibitors can significantly increase the intensity and duration of morphine antinociceptive activity via both alpha(2)-adrenergic and opioid receptors. This interaction was not observed with the selective serotonin inhibitor, citalopram.
Assuntos
Inibidores da Captação Adrenérgica/administração & dosagem , Analgésicos Opioides/administração & dosagem , Antidepressivos de Segunda Geração/administração & dosagem , Maprotilina/administração & dosagem , Morfina/administração & dosagem , Dor/prevenção & controle , Antagonistas Adrenérgicos alfa/administração & dosagem , Amitriptilina/administração & dosagem , Animais , Comportamento Animal/efeitos dos fármacos , Citalopram/administração & dosagem , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Sinergismo Farmacológico , Quimioterapia Combinada , Injeções Espinhais , Masculino , Naloxona/administração & dosagem , Antagonistas de Entorpecentes/administração & dosagem , Medição da Dor , Limiar da Dor/efeitos dos fármacos , Ratos , Ratos Wistar , Tempo de Reação/efeitos dos fármacos , Inibidores Seletivos de Recaptação de Serotonina/administração & dosagem , Fatores de Tempo , Ioimbina/administração & dosagemRESUMO
Many drugs block delayed rectifier K+ channels and prolong the cardiac action potential duration. Here we investigate the molecular mechanisms of voltage-dependent block of human ether-a-go-go-related gene (HERG) K+ channels expressed in cells HEK-293 and Xenopus oocytes by maprotiline. The IC50 determined at 0 mV on HERG expressed HEK-293 cell and oocytes was 5.2 and 23.7 microM, respectively. Block of HERG expressed in oocytes by maprotiline was enhanced by progressive membrane depolarization and accompanied by a negative shift in the voltage dependence of channel activation. The potency of maprotiline was reduced 7-fold by point mutation of a key aromatic residue (F656T) and 3-fold for Y652A, both located in the S6 domain. The mutation Y652A inverted the voltage dependence of HERG channel block by maprotiline. Together, these results suggest that voltage-dependent block of HERG results from gating dependent changes in the accessibility of Y652, a critical component of the drug binding site.
Assuntos
Antidepressivos de Segunda Geração/farmacologia , Canais de Potássio Éter-A-Go-Go/antagonistas & inibidores , Maprotilina/farmacologia , Animais , Sítios de Ligação , Relação Dose-Resposta a Droga , Canal de Potássio ERG1 , Estimulação Elétrica , Canais de Potássio Éter-A-Go-Go/genética , Canais de Potássio Éter-A-Go-Go/fisiologia , Feminino , Expressão Gênica , Humanos , Potenciais da Membrana/efeitos dos fármacos , Oócitos/efeitos dos fármacos , Oócitos/metabolismo , Oócitos/fisiologia , Mutação Puntual , XenopusAssuntos
Humanos , Criança , Adolescente , Transtornos do Humor/diagnóstico , Transtornos do Humor/terapia , Amitriptilina/administração & dosagem , Imipramina/administração & dosagem , Maprotilina/administração & dosagem , Nortriptilina/administração & dosagem , Transtorno Distímico/terapia , Carbamazepina/administração & dosagem , Citalopram/administração & dosagem , Fluoxetina/administração & dosagem , Carbonato de Lítio/administração & dosagem , Sertralina/administração & dosagem , Ácido Valproico/administração & dosagemRESUMO
Os medicamentos antidepressivos tornaram a depressäo um problema médico com elevado potencial tratavel. Nas últimas décadas houve um grande avanço na pesquisa e novos compostos surgiram. Os antidepressivos de primeira geraçäo tiveram seu uso limitado devido a tolerabilidade e toxicidade. Os novos compostos, embora mais seguros, näo se mostraram superiores aos antidepressivos tradicionais. Neste artigo o autor revisa a farmacologia e as indicaçöes dos antidepressivos, assim como as indicaçöes e a eficácia diferencial entre os compostos clássicos e de nova geraçäo(au)
Assuntos
Humanos , Antidepressivos , Depressão/tratamento farmacológico , Serotoninérgicos/uso terapêutico , Amitriptilina , Monoaminas Biogênicas , Bupropiona , Clomipramina , Desipramina , Doxepina , Imipramina , Inibidores Seletivos de Recaptação de Serotonina/uso terapêutico , MaprotilinaRESUMO
El autor hace un estudio retrospectivo de múltiples casos de depresión tratados con maprotilina (ludiomil). Utiliza la clasificación nosológica de Paul Kielholz y hace un estudio sobre dicho medicamento
Assuntos
Maprotilina , Maprotilina/uso terapêutico , Antidepressivos , Antidepressivos/uso terapêutico , Depressão/terapiaRESUMO
The role of para-chlorophenylalanine and alpha-methyl-DL-p-tyrosine in the antinociceptive effects of the intracerebroventricular administration of the antidepressant drugs clomipramine, zimelidine, imipramine and maprotiline was studied using the acetic acid writhing test in mice. The results demonstrated an antinociceptive effect for all these antidepressants. Pretreatment with para-chlorophenylalanine significantly reduced the antinociception induced by the ED50's of imipramine and maprotiline, and did not modify the effects of zimelidine and clomipramine, pretreatment with alpha-methyl-tyrosine did not modify the antinociception induced by these drugs except maprotiline. Pretreatment with para-chlorophenylalanine plus alpha-methyltyrosine significantly reduced the antinociceptive effect of all the antidepressants tested. The main finding of the present study is that the association of para-chlorophenylalanine plus alpha-methyltyrosine reduced the antinociceptive action of all the antidepressants. This means that critical levels of both 5-HT and NA are responsible for mediating the antinociceptive effects of antidepressants on the writhing test in mice.
Assuntos
Analgesia , Antidepressivos/farmacologia , Fenclonina/farmacologia , Metiltirosinas/farmacologia , Serotoninérgicos/farmacologia , Acetatos/administração & dosagem , Acetatos/intoxicação , Ácido Acético , Animais , Clomipramina/farmacologia , Interações Medicamentosas , Fenclonina/administração & dosagem , Imipramina/farmacologia , Injeções Intraventriculares , Maprotilina/administração & dosagem , Maprotilina/farmacologia , Metiltirosinas/administração & dosagem , Camundongos , Norepinefrina/metabolismo , Distribuição Aleatória , Serotonina/metabolismo , Serotoninérgicos/administração & dosagem , Zimeldina/farmacologia , alfa-MetiltirosinaRESUMO
Infusöes venosas de antidepressivos é utilizada como técnica de tratamento de Depressöes resistentes, em regime ambulatorial. Em estudo aberto com 33 pacientes, procura-se verificar a eficácia e tolerância do tratamento com infusöes. Duas substâncias, clomipramina (preferentemente serotoninérgica) e Maprotilina (noradrenérgica), säo utilizadas no estudo. Modificaçäo da técnica usual, com aumento do tempo de perfusäo, e cuidados clínicos, possibilitam a aplicaçäo em regime extra-hospitalar. Os resultados indicam evoluçäo favorável em mais de 80 por cento dos casos, com baixo nível de efeitos colaterais. Seguimento de um ano é considerado.
Assuntos
Humanos , Masculino , Feminino , Adolescente , Adulto , Pessoa de Meia-Idade , Assistência Ambulatorial , Antidepressivos Tricíclicos/uso terapêutico , Clomipramina/uso terapêutico , Transtorno Depressivo/tratamento farmacológico , Maprotilina/uso terapêutico , Antidepressivos Tricíclicos/administração & dosagem , Clomipramina/administração & dosagem , Infusões Intravenosas , Maprotilina/administração & dosagem , Resultado do TratamentoRESUMO
Neste artigo é exposto sucintamente aspectos do metabolismo dos antidepressivos tricíclicos (desmetilaçao e hipdroxilaçao) que devem ser levados em conta na interpretaçao das dosagens plasmáticas e efeitos clínicos destes medicamentos
Assuntos
Humanos , Masculino , Feminino , Amitriptilina/farmacocinética , Antidepressivos Tricíclicos/farmacologia , Antidepressivos Tricíclicos/metabolismo , Clomipramina/farmacocinética , Desipramina/farmacocinética , Doxepina/farmacocinética , Imipramina/farmacocinética , Maprotilina/farmacocinética , Mianserina/farmacocinética , Nortriptilina/farmacocinética , Protriptilina/farmacocinética , Viloxazina/farmacocinéticaAssuntos
Transtornos Cerebrovasculares/complicações , Transtorno Depressivo/etiologia , Adulto , Idoso , Transtorno Depressivo/tratamento farmacológico , Transtorno Depressivo/psicologia , Feminino , Humanos , Masculino , Maprotilina/uso terapêutico , Pessoa de Meia-Idade , Estudos Prospectivos , Escalas de Graduação PsiquiátricaRESUMO
Os autores apresentam inicialmente uma revisäo bibliográfica do uso de infusäo endovenosa em psicofarmacoterapia, como também as principais teorias neuroquímicas das depressöes de fundamento biológico